Veracyte's earnings call was positive overall, with strong revenue and volume growth, significant strategic milestones, and promising future product launches. While there were some financial challenges such as a decline in product revenue and increased operating expenses, the positive highlights significantly outweighed the lowlights.

Company Guidance -

Q3 2025

During Veracyte's second quarter 2025 financial results webcast, the company reported a 14% year-over-year revenue growth, totaling $130 million, driven primarily by a 14% increase in testing revenue, which rose to $122.3 million. The company's adjusted EBITDA margin reached an impressive 27.5%, surpassing expectations. Decipher tests experienced a 28% year-over-year volume growth, with approximately 25,500 tests delivered, indicating a strong trajectory towards exceeding 100,000 annual tests for the first time. Additionally, Afirma's volume grew by 8% year-over-year, with around 16,950 tests conducted. Veracyte's ongoing strategic initiatives include the successful launch of Decipher Prostate for metastatic patients, entry into a partnership with Helix, and plans to expand its MRD platform. The company's full-year 2025 revenue guidance ranges from $496 million to $504 million, with an updated adjusted EBITDA margin guidance of 23.5%.

Strong Revenue and Volume Growth

Veracyte delivered 14% revenue growth year-over-year with total revenue of $130 million and a 15% increase in test volume. Decipher and Afirma showed impressive volume growth, with Decipher growing 28% in volume year-over-year.

Decipher Test Milestones

Decipher delivered approximately 25,500 tests, on track to exceed 100,000 tests annually for the first time. This marks the 13th consecutive quarter of over 25% year-over-year volume growth.

Adjusted EBITDA Margin

Veracyte achieved an adjusted EBITDA margin of 27.5%, surpassing expectations and indicating strong financial performance.

Progress in Geographic Expansion

The French Commercial Court approved the sale of the contract manufacturing portion of Veracyte SAS, maintaining continuity of supply for the Prosigna IVD on nCounter.

Launch of New Offerings

Veracyte plans to launch Prosigna as an LDT in the U.S. breast cancer market by mid-2026, leveraging the PAM50 signature to inform treatment decisions.

Veracyte (VCYT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VCYT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.30 / -	0.19	―	―	―
Aug 06, 2025	2025 (Q2)	0.26 / 0.44	0.07	528.57% (+0.37)
May 07, 2025	2025 (Q1)	0.12 / 0.31	-0.02	1650.00% (+0.33)
Feb 24, 2025	2024 (Q4)	0.11 / 0.06	-0.39	115.38% (+0.45)
Nov 06, 2024	2024 (Q3)	0.03 / 0.19	-0.41	146.34% (+0.60)
Aug 06, 2024	2024 (Q2)	-0.02 / 0.07	-0.12	158.33% (+0.19)
May 07, 2024	2024 (Q1)	-0.16 / -0.02	-0.11	81.82% (+0.09)
Feb 22, 2024	2023 (Q4)	-0.10 / -0.39	-0.05	-680.00% (-0.34)
Nov 07, 2023	2023 (Q3)	-0.15 / -0.41	-0.12	-241.67% (-0.29)
Aug 08, 2023	2023 (Q2)	-0.15 / -0.12	-0.13	7.69% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VCYT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$23.97	$27.68	+15.48%
May 07, 2025	$30.84	$31.21	+1.20%
Feb 24, 2025	$39.36	$33.46	-14.99%
Nov 06, 2024	$36.59	$37.34	+2.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Veracyte (VCYT) report earnings?

Veracyte (VCYT) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Veracyte (VCYT) earnings time?

Veracyte (VCYT) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VCYT EPS forecast?

VCYT EPS forecast for the fiscal quarter 2025 (Q3) is 0.3.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing